Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

S Heller; J Buse; M Fisher; S Garg; M Marre; L Merker; E Renard; D Russell-Jones; A Philotheou; AM Francisco; H Pei; B Bode; BEGIN Basal-Bolus Type 1 Trial Investigators

doi:10.1016/S0140-6736(12)60204-9

Back

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Journal article

Peer reviewed

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

S Heller, J Buse, M Fisher, S Garg, M Marre, L Merker, E Renard, D Russell-Jones, A Philotheou, AM Francisco, …

Lancet, Vol.379(9825), pp.1489-1497

21/04/2012

DOI: https://doi.org/10.1016/S0140-6736(12)60204-9

Abstract

Adult

Diabetes Mellitus

Type 1

Drug Administration Schedule

Female

Hemoglobin A

Glycosylated

Humans

Hypoglycemic Agents

Insulin Aspart

Insulin

Long-Acting

Male

Intensive basal-bolus insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term complications that are associated with type 1 diabetes mellitus. Insulin degludec is a new, ultra-longacting basal insulin. We therefore compared the efficacy and safety of insulin degludec and insulin glargine, both administered once daily with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes.

Metrics

24 Record Views

280 Times Cited - Web of Science

See more details

Details

Title: Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Creators: S Heller
J Buse
M Fisher
S Garg
M Marre
L Merker
E Renard
D Russell-Jones
A Philotheou
AM Francisco
H Pei
B Bode
BEGIN Basal-Bolus Type 1 Trial Investigators
Publication Details: Lancet, Vol.379(9825), pp.1489-1497
Date published: 21/04/2012
Date submitted: 17/05/2017
Identifiers: 99514895402346
Academic Unit: University of Surrey
Language: English
Resource Type: Journal article

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Abstract

Metrics

Details

Usage Policy